[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-364491-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-364491-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","molecular-principles-underlying-aggressive-cancers","Molecular principles underlying aggressive cancers","","Aggressive cancers challenge conventional treatment by enabling rapid spread despite severe therapy and by sustaining strong drug resistance mechanisms. A foundational quantitative biophysics perspective links aggressiveness to high numbers of overexpressed or mutated key signaling proteins that remain in active conformations within major proliferation pathways. The review compares highly aggressive versus more treatable cancers, detailing oncogenic protein activation (e.g., ERK1/2) through chromatin malfunction and crosslinked signaling, and connecting these states to heightened heterogeneity, plasticity, and resistance. It derives molecular principles and outlines drug regimens and combinations across multiple cancer types, including PDAC, NSCLC, CRC, HCC, breast and prostate cancers, glioblastoma, neuroblastoma, and leukemia.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/molecular-principles-underlying-aggressive-cancers/364491/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/molecular-principles-underlying-aggressive-cancers/364491.png","ImageObject",300,407,{"name":42,"@type":43},"Hazel","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-02","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How does the review define aggressive cancers at the molecular level?","Question",{"text":63,"@type":64},"It links aggressiveness to large numbers of crucial signaling proteins that are overexpressed or mutated and populate active conformations in major proliferation pathways.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What molecular hallmark is described as foundational for aggressive cancers?",{"text":68,"@type":64},"Escalating loads of active oncogenic proteins paired with suppression of inactive tumor suppressors, reflected by conformational distributions that shape molecular and cellular function.",{"name":70,"@type":61,"acceptedAnswer":71},"Which cancer types and drug strategies are discussed?",{"text":72,"@type":64},"The review discusses principles and drug regimens—including single drugs and combinations—for PDAC, NSCLC, CRC, HCC, breast and prostate cancers, glioblastoma, neuroblastoma, and leukemia.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},364491,1791183443,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},137441390410,"https://ap-avatar.wpscdn.com/avatar/2000252f4ab5702993?_k=1776741390130283984","Signal Transduction [and Targeted Therapy](and Targeted Therapy www.nature.com/sigtrans)[ www.nature.com/sigtrans](and Targeted Therapy www.nature.com/sigtrans)  \nREVIEW ARTICLE OPEN  \nMolecular principles underlying aggressive cancers  \nRuth Nussinov 1,2,3 ✉, Bengi Ruken Yavuz2 and Hyunbum Jang 1,2  \n\n| | Aggressive tumors pose ultra-challenges to drug resistance. Anti-cancer treatments are often unsuccessful, and single-cell technologies to rein drug resistance mechanisms are still fruitless. The National Cancer Institute deﬁnes aggressive cancers at the tissue level, describing them as those that spread rapidly, despite severe treatment. At the molecular, foundational level, the quantitative biophysics discipline deﬁnes aggressive cancers as harboring a large number of (overexpressed, or mutated) crucial signaling proteins in major proliferation pathways populating their active conformations, primed for their signal transduction roles. This comprehensive review explores highly aggressive cancers on the foundational and cell signaling levels, focusing on the differences between highly aggressive cancers and the more treatable ones. It showcases aggressive tumors as harboring massive, cancer-promoting, catalysis-primed oncogenic proteins, especially through certain overexpression scenarios, as predisposed aggressive tumor candidates. Our examples narrate strong activation of ERK1/2, and other oncogenic proteins, through malfunctioning chromatin and crosslinked signaling, and how they activate multiple proliferation pathways. They show the increased cancer heterogeneity, plasticity, and drug resistance. Our review formulates the principles underlying cancer aggressiveness on the molecular level, discusses scenarios, and describes drug regimen (single drugs and drug combinations) for PDAC, NSCLC, CRC, HCC, breast and prostate cancers, glioblastoma, neuroblastoma, and leukemia as examples. All show overexpression scenarios of master transcription factors, transcription factors with gene fusions, copy number alterations, dysregulation of the epigenetic codes and epithelial-to-mesenchymal transitions in aggressive tumors, as well as high mutation | |\n| --- | --- | --- |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  | loads of vital upstream signaling regulators, such as EGFR, c-MET, and K-Ras, beﬁtting these principles. |  |\n|  |  |  |\n|  |  |  |\n|  | Signal Transduction and Targeted Therapy (2025)10:42 ; [https://doi.org/10.1038/s41392-025-02129-7](https://doi.org/10.1038/s41392-025-02129-7) |  |\n|  |  |  |\n\nINTRODUCTION  \nAggressive cancers have been associated with multiple factors.1–5 This comprehensive review chronicles several highly aggressive cancers, their drug regimen, and their accelerated growth and malignancy. It explores the fundamental differences between highly aggressive cancers and the less aggressive, more treatable ones. Especially, it focuses on their underlying principles on the fundamental molecular and cell signaling levels. It formulates their hallmarks and weighs the clues that they provide to anti-cancer drug combination strategies targeting their ultra-strong drug resistance. Without exceptions, the examples of aggressive cancers that it narrates—all labeled by the clinical literature as highly aggressive—reveal scenarios promoting overexpression of oncogenic proteins, suppression of tumor suppressors, and crucially, altered expression of their regulators (e.g., see refs. 6–11; reviewed below) . Potent oncogenic mutations, especially in upstream regulators, are common. The review further discusses the outcome: a massive payload of catalysis-ready conformational states, accompanied by powerful and heterogenous cell signaling. Tumors harboring massive increases in the numbers of active molecules of relevant oncogenic proteins, especially through certain immense overexpression framework","cbCaikWhFD76jATx","https://ap.wps.com/l/cbCaikWhFD76jATx","pdf",4361153,27,"English","# Introduction\n## Molecular hallmark of aggressive cancers\n# Molecular principles and signaling differences\n## Oncogenic protein activation and conformational states\n## Effects on heterogeneity, plasticity, and resistance\n# Drug regimens and combinations across cancer types","[{\"question\":\"How does the review define aggressive cancers at the molecular level?\",\"answer\":\"It links aggressiveness to large numbers of crucial signaling proteins that are overexpressed or mutated and populate active conformations in major proliferation pathways.\"},{\"question\":\"What molecular hallmark is described as foundational for aggressive cancers?\",\"answer\":\"Escalating loads of active oncogenic proteins paired with suppression of inactive tumor suppressors, reflected by conformational distributions that shape molecular and cellular function.\"},{\"question\":\"Which cancer types and drug strategies are discussed?\",\"answer\":\"The review discusses principles and drug regimens—including single drugs and combinations—for PDAC, NSCLC, CRC, HCC, breast and prostate cancers, glioblastoma, neuroblastoma, and leukemia.\"}]","Molecular principles underlying aggressive cancers | PDF",1790157775,68,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/54ff865989f865bae9f15484189235a7.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d52304f15fb91b4b39ebed35a78ebf23.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ab05414255ededb7a98c5162952eef0f.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ec8ebf5a2ff5a486a4e371a389385875.webp",980,1301]